{"groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"FG000","title":"Idelalisib + Rituximab"},{"description":"Placebo to match idelalisib administered orally twice daily plus rituximab (8 intravenous doses through Week 20: Day 1: 375 mg/m\\^2, and 500 mg/m\\^2 thereafter)","id":"FG001","title":"Placebo + Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Richter's Transformation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"110"},{"groupId":"FG001","numSubjects":"110"}],"type":"STARTED"},{"achievements":[{"comment":"Completed=reached primary efficacy endpoint (progressive disease or death) or finished study period.","groupId":"FG000","numSubjects":"87"},{"comment":"Completed=reached primary efficacy endpoint (progressive disease or death) or finished study period.","groupId":"FG001","numSubjects":"97"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were enrolled at a total of 53 study sites in the United States and Europe. The first participant was screened on 03 April 2012. The last study visit occurred on 20 April 2014."}